stockrowBeam Therapeutics Inc.
BEAM Healthcare Biotechnology
Beam Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $139.7 million, up 120.0% from fiscal 2024.
- Revenue
- −96.8%
- EPS
- −16.7%
- Free cash flow
- −29.5%
Quarter to September 2026, against a year earlier
Follow BEAM
Alert me
Beam Therapeutics Inc. (BEAM) EBITDA
Beam Therapeutics Inc.'s EBITDA for fiscal 2025 was −$377.4M, compared with −$416.4M in fiscal 2024. Over the twelve months to 30 September 2026 it was −$381.7M. Over the past ten years it has ranged from −$416.4M (fiscal 2024) to −$7.9M (fiscal 2017); the current reading is higher than 33% of that period. Beam Therapeutics Inc. ranks 562nd of 594 Biotechnology companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | −$377.4M | — |
| FY2024 | −$416.4M | — |
| FY2023 | −$186.2M | — |
| FY2022 | −$333.7M | — |
| FY2021 | −$385.1M | — |
| FY2020 | −$127.9M | — |
| FY2019 | −$72.6M | — |
| FY2018 | −$45.1M | — |
| FY2017 | −$7.9M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Sep 2026 | −$138.6M | — |
| Jun 2026 | −$123.7M | — |
| Mar 2026 | −$104.3M | — |
| Dec 2025 | −$15.0M | — |
| 27 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| MBX MBX Biosciences, Inc. compare | −$117.7M |
| XNCR Xencor, Inc. compare | −$209.4M |
| NAMS NewAmsterdam Pharma Company N.V. compare | −$233.2M |
| ZLAB Zai Lab Limited Unsponsored ADR compare | −$253.7M |
| BEAM Beam Therapeutics Inc. | −$381.7M |
| IDYA IDEAYA Biosciences, Inc. compare | −$463.5M |
| VRDN Viridian Therapeutics, Inc. compare | −$474.6M |
| RCUS Arcus Biosciences, Inc. compare | −$488.0M |
| TLX Telix Pharmaceuticals Limited compare | — |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on BEAM
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement